New scan spots prostate cancers standard MRI misses

NCT ID NCT04461509

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tested whether a high-resolution PET-MRI scan using a prostate-specific tracer (18F-PSMA) can find cancers that standard MRI might miss. 62 men with prostate cancer considering focal therapy or surgery received both scans, and results were checked with biopsies. The goal was to see if the advanced imaging improves cancer mapping before treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-PSMA (18F-DCFPyL injection, a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging approach could help doctors map prostate cancer more accurately, potentially reducing the chance of missing aggressive tumors before treatment.
What could go wrong
This is a small Phase 2 study (62 participants) focused on imaging accuracy, not treatment outcomes. The results may not apply to all prostate cancer patients or change standard care yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENITAL DISEASES, MALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.